Phaseline

Targets › TNFRSF6B

TNFRSF6B (Tumor necrosis factor receptor superfamily member 6B): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 4; Oncology; next expected readout Mar 2027.

Soluble decoy receptor that binds and neutralizes the TNF-family ligands TNFSF14/LIGHT, TNFSF15, and FASLG, preventing them from interacting with their cognate receptors and thereby blocking apoptosis and other immune-signaling pathway. (UniProt, O95407)

Open in Phaseline: the race on TNFRSF6B, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Julie GehlBleomycin
DNA-damaging chemotherapy agent; bleomycin causes DNA strand breaks and inhibits DNA synth
TNFRSF6BPhase 4Cutaneous MetastasisMar 2027

Conditions

Cutaneous Metastasis (1)

Modalities

small molecule (1)

Companies

Julie Gehl (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.